Newly published data from a cohort of patients receiving doxorubicin-containing regimens for newly diagnosed T-cell acute lymphoblastic leukaemia or lymphoblastic non-Hodgkin lymphoma reveal that addition of dexrazoxane ameliorates the cardiotoxic effects of doxorubicin. No significant differences in overall survival, or in the incidence of treatment-related adverse events were observed; however, significant improvements were observed in a range of cardiac parameters in the dexrazoxane plus chemotherapy group; these effects were sustained up to 6.4 years after diagnosis.
References
Asselin, B. L. et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.60.8851
Rights and permissions
About this article
Cite this article
Sidaway, P. Dexrazoxane confers cardioprotection. Nat Rev Clin Oncol 13, 134 (2016). https://doi.org/10.1038/nrclinonc.2016.4
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.4